274 related articles for article (PubMed ID: 8946904)
1. Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan.
Kessler DA; Hass AE; Feiden KL; Lumpkin M; Temple R
JAMA; 1996 Dec; 276(22):1826-31. PubMed ID: 8946904
[TBL] [Abstract][Full Text] [Related]
2. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
Rawson NS
CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
[TBL] [Abstract][Full Text] [Related]
3. Delays in psychiatric drug development in Japan.
Shimazawa R; Kusumi I; Ikeda M
J Clin Pharm Ther; 2012 Jun; 37(3):348-51. PubMed ID: 22017294
[TBL] [Abstract][Full Text] [Related]
4. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
[TBL] [Abstract][Full Text] [Related]
5. The FDA's drug review process: ensuring drugs are safe and effective.
Meadows M
FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
[No Abstract] [Full Text] [Related]
6. Obtaining drugs from foreign markets.
Shirk MB; Hale KN
Am J Hosp Pharm; 1992 Nov; 49(11):2731-9. PubMed ID: 1471638
[TBL] [Abstract][Full Text] [Related]
7. A Comparative Study of the Market Configuration of the Japanese Pharmaceutical Market Using the Gini Coefficient and Herfindahl-Hirschman Index.
Shibata S; Fukumoto D; Suzuki T; Ozaki K
Ther Innov Regul Sci; 2020 Sep; 54(5):1047-1055. PubMed ID: 31989539
[TBL] [Abstract][Full Text] [Related]
8. Food and Drug Administration Drug Approval Process: A History and Overview.
Williams CT
Nurs Clin North Am; 2016 Mar; 51(1):1-11. PubMed ID: 26897420
[TBL] [Abstract][Full Text] [Related]
9. 1992 Le Tourneau Award. Problems with pharmaceutical regulation in the United States. Drug lag and orphan drugs.
Henry V
J Leg Med; 1993 Dec; 14(4):617-39. PubMed ID: 8308452
[No Abstract] [Full Text] [Related]
10. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
11. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
12. Sanofi Pharmaceuticals, Inc., et al.; withdrawal of approval of 21 new drug applications and 62 abbreviated new drug applications--FDA. Notice.
Fed Regist; 1998 May; 63(91):26191-3. PubMed ID: 10179336
[TBL] [Abstract][Full Text] [Related]
13. Whatever happened to user fees and the FDA's promise to expedite new drug approvals?
Gatty B
Hosp Formul; 1993 Jul; 28(7):656, 655. PubMed ID: 10127048
[No Abstract] [Full Text] [Related]
14. Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made?
Rawson NS
Clin Ther; 2003 Apr; 25(4):1230-47. PubMed ID: 12809970
[TBL] [Abstract][Full Text] [Related]
15. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
16. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
Schultheis LW; Rappaport BA
Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
[No Abstract] [Full Text] [Related]
17. Obstacles and opportunities in new drug development.
Kaitin KI
Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685
[No Abstract] [Full Text] [Related]
18. Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
Arnold DG; Troyer JL
J Health Polit Policy Law; 2016 Apr; 41(2):157-79. PubMed ID: 26732315
[TBL] [Abstract][Full Text] [Related]
19. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
20. Drug pipeline: 3Q15.
DeFrancesco L
Nat Biotechnol; 2015 Nov; 33(11):1126. PubMed ID: 26544135
[No Abstract] [Full Text] [Related]
[Next] [New Search]
